SCHEMBL6325965

SCHEMBL6325965

O=C(O)CCc1nc(-c2cccc(COC(F)F)c2)no1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 10/20 0.53
ALDH1A1 P00352 1/20 0.52
TSHR P16473 2/20 0.51
LMNA P02545 1/20 0.51
ATM Q13315 1/20 0.51
KMT2A Q03164 1/20 0.50
MITF O75030 1/20 0.49
TP53 P04637 1/20 0.49
NCOA3 Q9Y6Q9 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
MAPK1 P28482 2/20 0.47
HTT P42858 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325325 0.89 KMT2A (0.50) FFAR1ALDH1A1TSHRKMT2ACYP1A2
SCHEMBL6326390 0.86 TSHR (0.62) FFAR1ALDH1A1TSHRLMNAATM
SCHEMBL6326668 0.83 MITF (0.58) FFAR1ALDH1A1TSHRLMNAATM
SCHEMBL6326326 0.82 ALDH1A1 (0.59) FFAR1ALDH1A1TSHRLMNAATM
SCHEMBL6326164 0.80 ALDH1A1 (0.63) FFAR1ALDH1A1TSHRLMNAATM
SCHEMBL6324746 0.79 TSHR (0.55) FFAR1ALDH1A1TSHRLMNAATM
SCHEMBL5330405 0.77 ALDH1A1 (0.83) FFAR1ALDH1A1TSHRLMNAATM
SCHEMBL1544736 0.77 TSHR (0.71) FFAR1ALDH1A1TSHRLMNAATM
SCHEMBL6324430 0.77 MAPK1 (0.73) FFAR1ALDH1A1TSHRLMNAATM
SCHEMBL6326329 0.76 FFAR1 (0.60) FFAR1ALDH1A1TSHRLMNAATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 FFAR1 2536/4885ALDH1A1 338/4885TSHR 4656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.